β型钛合金材料的生物相容性评价  

Evaluation on Biocompatibility of β-type Titanium Alloys

作　　者：张明华[1] 于振涛[2] 周廉[2] 张殿忠[1] 

机构地区：[1]第四军医大学唐都医院全军骨肿瘤研究所,陕西西安710038 [2]西北有色金属研究院,陕西西安710016

出　　处：《稀有金属材料与工程》2007年第10期1815-1819,共5页Rare Metal Materials and Engineering

基　　金：国家高技术研究发展计划("863"计划)(2002AA326070)

摘　　要：通过皮下、肌肉植入试验评价两种β型钛合金材料TLE(Ti-(3～6)Zr-(2～4)Mo(24～27)Nb),TLM2(Ti-(1.5～4.5)Zr-(0.5～5.5)Sn-(1.5～4.4)Mo-(23.5～26.5)Nb)的生物相容性。将TLE,TLM2两种新型医用钛合金和对照材料(Ti-6Al-4V)分别植入家兔皮下和肌肉内,依据GB/T16886.6-1997标准,在1,2,6,12,24周作大体观察评价和组织学检查。结果表明:两种β型钛合金材料炎细胞浸润情况与对照材料无明显差异、包膜的厚度比对照材料薄,TLE和TLM2新型医用钛合金生物相容性良好。The aim of the study is to evaluate the in vivo biocompatibility to two novel β-type titanium alloys： TLE （Ti-（3-6）Zr-（2-4）Mo（24-27）Nb）, TLM 2（Ti-（1.5-4.5） Zr-（0.5~5.5） Sn-（1.5~4.4）Mo-（23.5~26.5）Nb）. The two titanium alloys （TLE,TLM2） and the contrast alloy （Ti-6Al-4V） were implanted subcutaneously and intramuscularly in rabbits. According to GB/T16886.6-1997 standard, the macroscopic observations and histologic examination were carried out for 1, 2, 6, 12 and 24 weeks after the implantation. Result show that the degree of inflammation presents no difference between the two new β-type titanium alloys （TLE, TLM 2） and the contrast alloy （Ti-6Al-4V）, the thicknesses of the capsules of the two novel β-type titanium alloys are thinner than those of the contrast alloy. The two new β-type Titanium alloys （TLE, TLM 2） have good biocompatibility.

关 键 词：Β型钛合金 生物相容性 植入试验 

分 类 号：R318.08[医药卫生—生物医学工程]